{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:20:33Z","timestamp":1791062433957,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011042","name":"Pfizer Scientific Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009459","name":"Society for Anthropological Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004784","name":"SAS Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ygyno.2025.05.022","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T14:42:39Z","timestamp":1749652959000},"page":"161-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018)"],"prefix":"10.1016","volume":"198","author":[{"given":"Fernanda Bronzon","family":"Damian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia Cristina","family":"De Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziela Z.","family":"Dal Molin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lica","family":"Nogueira-Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aknar","family":"Calabrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Werutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias Abdo","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiane Francieli","family":"Rebelatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela Gomes","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela Foresti","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2025.05.022_bb0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.05.022_bb0010","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.05.022_bb0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.05.022_bb0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","article-title":"Second-line treatment of ovarian Cancer","volume":"5","author":"Markman","year":"2000","journal-title":"Oncologist"},{"issue":"17_suppl","key":"10.1016\/j.ygyno.2025.05.022_bb0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5507","volume":"41","author":"Moore","year":"2023","journal-title":"JCO"},{"issue":"13","key":"10.1016\/j.ygyno.2025.05.022_bb0030","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.ygyno.2025.05.022_bb0035","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.steroids.2013.01.008","article-title":"New insights on the role of hormonal therapy in ovarian cancer","volume":"78","author":"Simpkins","year":"2013","journal-title":"Steroids"},{"issue":"9","key":"10.1016\/j.ygyno.2025.05.022_bb0040","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol."},{"issue":"35","key":"10.1016\/j.ygyno.2025.05.022_bb0045","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial","volume":"33","author":"Eeles","year":"2015","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.ygyno.2025.05.022_bb0050","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s13402-021-00600-5","article-title":"Functional estrogen receptor signaling pathway activity in high-grade serous ovarian carcinoma as compared to estrogen receptor protein expression by immunohistochemistry","volume":"44","author":"Van Der Ploeg","year":"2021","journal-title":"Cell. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.05.022_bb0055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","article-title":"The broken cycle: E2F dysfunction in cancer","volume":"19","author":"Kent","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2025.05.022_bb0060","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ygyno.2025.05.022_bb0065","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2025.05.022_bb0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.05.022_bb0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ygyno.2025.05.022_bb0080","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ygyno.2023.06.466","article-title":"GOG 3026 a phase II trial of letrozole + ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum: a GOG foundation study (001)","volume":"176","author":"Slomovitz","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.05.022_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Colon-Otero","year":"2020","journal-title":"ESMO Open"},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2025.05.022_bb0090","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.2016.34.15_suppl.555","article-title":"A test utilising diagnostic and on-treatment biomarkers to improve prediction of response to endocrine therapy in breast cancer","volume":"34","author":"Turnbull","year":"2016","journal-title":"JCO"},{"key":"10.1016\/j.ygyno.2025.05.022_bb0095","article-title":"Palbociclib in the treatment of recurrent ovarian cancer","volume":"34","author":"Lee","year":"2020","journal-title":"Gynecol. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.ygyno.2025.05.022_bb0100","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical trials in recurrent ovarian cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2025.05.022_bb0105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2025.05.022_bb0110","first-page":"2233","article-title":"CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup","volume":"8","author":"Bowman","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2025.05.022_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100229","article-title":"Clinical benefit of systemic therapies for recurrent ovarian cancer\u2014ESMO-MCBS scores","volume":"6","author":"Broekman","year":"2021","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.ygyno.2025.05.022_bb0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.12998\/wjcc.v1.i6.187","article-title":"Recurrent epithelial ovarian cancer and hormone therapy","volume":"1","author":"Yokoyama","year":"2013","journal-title":"WJCC"},{"issue":"03","key":"10.1016\/j.ygyno.2025.05.022_bb0125","doi-asserted-by":"crossref","DOI":"10.26502\/jcsct.5079072","article-title":"Efficacy of anti-estrogen therapy in estrogen receptor positive high-grade serous ovarian carcinoma: a systematic review","volume":"04","author":"Van Der Ploeg","year":"2020","journal-title":"J. Cancer Sci. Clin. Ther."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:43:43Z","timestamp":1762231423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825008558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"alternative-id":["S0090825825008558"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.05.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}